Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats

Diabetes Research and Clinical Practice

Volumn 73, Issue 1, 2006, Pages 17-22

  Hasanein, Parisa ^a   Parviz, Mohsen ^b   Keshavarz, Mansoor ^b   Javanmardi, Kazem ^c   Mansoori, Marzieh ^b   Soltani, Nepton ^d  

^a BU ALI SINA UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Hyperalgesia; Hyperglycemia; Neuropathy; Rats

Indexed keywords

GLUCOSE; MAGNESIUM; MAGNESIUM SULFATE; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERALGESIA; MAGNESIUM BLOOD LEVEL; MALE; NONHUMAN; PAIN THRESHOLD; RAT; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HEAT; HOT TEMPERATURE; HYPERALGESIA; MAGNESIUM; MAGNESIUM SULFATE; MALE; RATS; RATS, WISTAR;

EID: 33646774339     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.12.004     Document Type: Article

References (46)

1. Brown M.J., Martin J.R., and Asbury A.K. Painful diabetic neuropathy. A morphometric study. Arch. Neurol. 33 3 (1976) 164-171
2. Obrosova I.G. Update on the pathogenesis of diabetic neuropathy. Curr. Diab. Rep. 3 6 (2003) 439-445
3. Tentolouris N., Pagoni S., Tzonou A., and Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. Eur. J. Intern. Med. 12 1 (2001) 20-27
4. Young M.J., Boulton A.J., MacLeod A.F., Williams D.R., and Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36 2 (1993) 150-154
5. Calcutt N.A. Modeling diabetic sensory neuropathy in rats. Methods Mol. Med. 99 (2004) 55-65
6. Greene D.A., Stevens M.J., and Feldman E.L. Diabetic neuropathy: scope of the syndrome. Am. J. Med. 107 2B (1999) 2S-8S
7. van der Naalt J., Fidler V., and Oosterhuis H.J. Vibration perception threshold, complaints and sensory examination in diabetic patients. Acta Neurol. Scand. 83 5 (1991) 297-300
8. Sounvoravong S., Nakashima M.N., Wada M., and Nakashima K. Decrease in serotonin concentration in raphe magnus nucleus and attenuation of morphine analgesia in two mice models of neuropathic pain. Eur. J. Pharmacol. 484 2-3 (2004) 217-223
9. Lee J.H., and McCarty R. Pain threshold in diabetic rats: effects of good versus poor diabetic control. Pain 50 2 (1992) 231-236
10. Calcutt N.A., Freshwater J.D., and Mizisin A.P. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47 4 (2004) 718-724
11. Courteix C., Eschalier A., and Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 1 (1993) 81-88
12. Forman L.J., Estilow S., Lewis M., and Vasilenko P. Streptozocin diabetes alters immunoreactive beta-endorphin levels and pain perception after 8 wk in female rats. Diabetes 35 12 (1986) 1309-1313
13. Lee J.H., and McCarty R. Glycemic control of pain threshold in diabetic and control rats. Physiol. Behav. 47 2 (1990) 225-230
14. Gupta M., Singh J., Sood S., and Arora B. Mechanism of antinociceptive effect of nimodipine in experimental diabetic neuropathic pain. Methods Find. Exp. Clin. Pharmacol. 25 1 (2003) 49-52
15. Malcangio M., and Tomlinson D.R. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76 1-2 (1998) 151-157
16. Zurek J.R., Nadeson R., and Goodchild C.S. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain 90 1-2 (2001) 57-63
17. Elamin A., and Tuvemo T. Magnesium and insulin-dependent diabetes mellitus. Diab. Res. Clin. Pract. 10 3 (1990) 203-209
18. Soltani N., Keshavarz M., Minaii B., Mirershadi F., Asl S.Z., and Dehpour A.R. Effects of administration of oral magnesium on plasma glucose and pathological changes in the aorta and pancreas of diabetic rats. Clin. Exp. Pharmacol. Physiol. 32 8 (2005) 604-610
19. Soltani N., Keshavarz M., Sohanaki H., Dehpour A.R., and Asl S.Z. Oral magnesium administration prevents vascular complications in STZ-diabetic rats. Life Sci. 76 13 (2005) 1455-1464
20. Laurant P., Touyz R.M., and Schiffrin E.L. Effect of magnesium on vascular tone and reactivity in pressurized mesenteric resistance arteries from spontaneously hypertensive rats. Can. J. Physiol. Pharmacol. 75 4 (1997) 293-300
21. Grafton G., Bunce C.M., Sheppard M.C., Brown G., and Baxter M.A. Effect of Mg2+ on Na(+)-dependent inositol transport. Role for Mg2+ in etiology of diabetic complications. Diabetes 41 1 (1992) 35-39
22. Djurhuus M.S., Skott P., Hother-Nielson O., Klitgaard N.A., and Beck-Nielsen H. Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinaemic states. Diab. Med. 12 8 (1995) 664-669
23. Rude R.K. Magnesium deficiency and diabetes mellitus. Causes and effects. Postgrad. Med. 92 5 (1992) 214-217
24. Garland H.O. New experimental data on the relationship between diabetes mellitus and magnesium. Magnes. Res. 5 3 (1992) 193-202
25. Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch. Intern. Med. 156 11 (1996) 1143-1148
26. Lima M.L., Cruz T., Pousada J.C., Rodrigues L.E., Barbosa K., and Cangucu V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diab. Care 21 5 (1998) 682-686
27. Engelen W., Bouten A., De Leeuw I., and De Block C. Are low magnesium levels in type 1 diabetes associated with electromyographical signs of polyneuropathy?. Magnes. Res. 13 3 (2000) 197-203
28. De Leeuw I., Engelen W., De Block C., and Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes. Res. 17 2 (2004) 109-114
29. Bonnefont-Rousselot D. The role of antioxidant micronutrients in the prevention of diabetic complications. Treat. Endocrinol. 3 1 (2004) 41-52
30. Djurhuus M.S., Klitgaard N.A., Pedersen K.K., Blaabjerg O., Altura B.M., Altura B.T., et al. Magnesium reduces insulin-stimulated glucose uptake and serum lipid concentrations in type 1 diabetes. Metabolism 50 12 (2001) 1409-1417
31. Lal J., Vasudev K., Kela A.K., and Jain S.K. Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. J. Assoc. Physicians India 51 (2003) 37-42
32. Yokota K., Kato M., Lister F., Ii H., Hayakawa T., Kikuta T., et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J. Am. Coll. Nutr. 23 5 (2004) 506S-509S
33. Spruce M.C., Potter J., and Coppini D.V. The pathogenesis and management of painful diabetic neuropathy: a review. Diab. Med. 20 2 (2003) 88-98
34. Begon S., Pickering G., Eschalier A., and Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res. 887 2 (2000) 436-439
35. Begon S., Pickering G., Eschalier A., and Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology 96 3 (2002) 627-632
36. Nowak L., Bregestovski P., Ascher P., Herbet A., and Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307 5950 (1984) 462-465
37. Mayer M.L., Westbrook G.L., and Guthrie P.B. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309 5965 (1984) 261-263
38. Dobretsov M., Hastings S.L., Romanovsky D., Stimers J.R., and Zhang J.M. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res. 960 1-2 (2003) 174-183
39. Dickenson A.H., Chapman V., and Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen. Pharmacol. 28 5 (1997) 633-638
40. Woolf C.J., and Thompson S.W. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 44 3 (1991) 293-299
41. Cameron N.E., Cotter M.A., Archibald V., Dines K.C., and Maxfield E.K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37 5 (1994) 449-459
42. van Dam P.S., van Asbeck B.S., Erkelens D.W., Marx J.J., Gispen W.H., and Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diab. Metab. Rev. 11 3 (1995) 181-192
43. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab. Metab. Rev. 11 3 (1995) 193-225
44. Paolisso G., Tirelli A., Coppola L., Verrazzo G., Pizza G., Sgambato S., et al. Magnesium administration reduces platelet hyperaggregability in NIDDM. Diab. Care 12 2 (1989) 167-168
45. Huang T.J., Sayers N.M., Fernyhough P., and Verkhratsky A. Diabetes-induced alterations in calcium homeostasis in sensory neurones of streptozotocin-diabetic rats are restricted to lumbar ganglia and are prevented by neurotrophin-3. Diabetologia 45 4 (2002) 560-570
46. Kruglikov I., Gryshchenko O., Shutov L., Kostyuk E., Kostyuk P., and Voitenko N. Diabetes-induced abnormalities in ER calcium mobilization in primary and secondary nociceptive neurons. Pflugers Arch. 448 4 (2004) 395-401